How should unfractionated heparin or low‑molecular‑weight heparin be bridged to warfarin in patients with acute limb ischemia, including dosing, INR targets, and duration?

Bridging Heparin to Warfarin in Acute Limb Ischemia

Start unfractionated heparin (UFH) immediately with an 80 U/kg IV bolus followed by 18 U/kg/hour continuous infusion, begin warfarin 5 mg daily on day 1, overlap both agents for a minimum of 5 days, and discontinue heparin only after INR reaches 2.0-3.0 for at least 24 consecutive hours.

Initial Anticoagulation Strategy

Unfractionated Heparin Dosing

Start UFH using weight-based dosing 1, 2:

• Initial bolus: 80 U/kg IV
• Continuous infusion: 18 U/kg/hour
• Target aPTT: 1.5-2.5 times normal (corresponding to anti-Factor Xa level 0.3-0.7 IU/mL)
• Monitor aPTT every 6 hours initially until stable therapeutic range achieved

Alternative if IV access problematic: Subcutaneous UFH 333 U/kg initial dose, then 250 U/kg twice daily 1. This unmonitored regimen has proven equally safe and effective as IV UFH for acute thrombotic events 1.

Why UFH Over LMWH in Acute Limb Ischemia

While guidelines prefer LMWH over UFH for venous thromboembolism 1, acute limb ischemia represents a distinct clinical scenario. UFH offers critical advantages:

• Immediate reversibility with protamine if emergency surgery becomes necessary
• Shorter half-life allowing rapid adjustment if bleeding complications arise
• No renal accumulation concerns in patients with compromised perfusion

Warfarin Initiation and Overlap

Starting Warfarin

Begin warfarin on day 1 of heparin therapy 3:

• Initial dose: 5 mg daily (typical starting dose)
• Lower initial doses (2.5 mg) for elderly patients, poor nutritional status, concurrent medications affecting metabolism, or underlying liver disease 1
• Target INR: 2.0-3.0 1, 4

Critical Overlap Period

Continue full-dose heparin for minimum 5 days AND until INR ≥2.0 for at least 24 hours 1, 5, 3. This dual requirement is essential because:

• Warfarin initially creates a paradoxical prothrombotic state by depleting protein C before depleting clotting factors
• Therapeutic INR alone does not guarantee adequate anticoagulation in the first 48 hours
• Early heparin discontinuation increases thrombotic risk despite therapeutic INR

Monitoring During Overlap

• Daily INR until stable therapeutic range achieved
• aPTT every 6 hours initially, then daily once stable
• Platelet count every 2-3 days from day 4 to day 14 to screen for heparin-induced thrombocytopenia (HIT risk up to 5% with UFH) 1
• Hemoglobin and hematocrit every 2-3 days 4

Discontinuing Heparin

Stop heparin when both criteria met 1, 5, 3:

1. Minimum 5 days of overlap completed
2. INR 2.0-3.0 for 2 consecutive measurements at least 24 hours apart

No tapering required - discontinue abruptly once criteria met 2, 3.

Special Considerations and Pitfalls

Timing of INR Measurements

If patient receiving both heparin and warfarin, draw blood for INR 3:

• ≥5 hours after last IV heparin bolus
• ≥4 hours after stopping continuous IV infusion
• ≥24 hours after subcutaneous heparin injection

This prevents heparin interference with INR measurement.

Renal Dysfunction

In patients with severe renal impairment (CrCl <30 mL/min):

• UFH is preferred over LMWH (which accumulates and is contraindicated) 1, 4
• Consider fixed-dose subcutaneous UFH 17,500-20,000 units every 12 hours (approximately 223-245 units/kg/dose) as demonstrated safe in ESRD patients 6

If Surgery Required During Bridging

UFH's short half-life allows:

• Stop infusion 4-6 hours pre-procedure for most operations
• Immediate reversal with protamine sulfate if emergency surgery needed
• Resume 12-24 hours post-operatively depending on bleeding risk

High Bleeding Risk Scenarios

For patients at elevated bleeding risk:

• Delay warfarin initiation 24-48 hours until hemodynamic stability confirmed
• Resume heparin 48-72 hours post-operatively rather than 12-24 hours 7
• Consider intermediate-dose LMWH (enoxaparin 40 mg twice daily) if transitioning from UFH after acute phase 7

Contraindications to Bridging

Absolute contraindications 8:

• Active major bleeding (>2 units transfused in 24 hours)
• Recent CNS bleed or high-risk intracranial lesion
• Thrombocytopenia <50,000/mcL
• Severe platelet dysfunction

Alternative: LMWH Bridging (If UFH Not Feasible)

If UFH truly not available or patient requires outpatient bridging after initial stabilization 1:

• Enoxaparin: 1 mg/kg subcutaneous twice daily OR 1.5 mg/kg once daily
• Dalteparin: 200 U/kg subcutaneous once daily
• Same overlap requirements (minimum 5 days + INR ≥2.0 for 24 hours)
• Caution: Avoid if CrCl <30 mL/min

However, for acute limb ischemia specifically, UFH remains the superior choice given the unpredictable clinical course and potential need for urgent surgical intervention 9.